The Innovative Therapy of “Gastric Bypass Stent System” from Tongee Medical Debuts at the 2nd China Obesity Congress

Synopsis:

In order to explore the solutions to the health problems of obese people, and in response to the national "Healthy China Strategy 2030", the Second China Obesity Congress (COC2023) was held in Beijing on July 29-30, which was jointly organized by the National Clinical Center for Digestive Diseases (Beijing), the Weight Loss and Metabolism Specialist Branch of Beijing Medical Doctor Association and related academic organizations.

On July 30, the exchange meeting on innovative therapy of gastric bypass stent hosted by Tongee Medical was held as scheduled. Professor Li Peng, the chief physician, professor and doctoral tutor of Beijing Friendship Hospital affiliated to Capital Medical University, was invited to preside over the meeting, and Professor Zhou Yanhua, deputy chief physician of the Department of Gastroenterology, Beijing Friendship Hospital affiliated to Capital Medical University, and Professor Zhao Xiangwen, vice president and director of Weight Loss Center of Zhongshan Xiaolan People's Hospital, were invited to share wonderful academic content.

At the CEO Forum of Weight-loss Medical Industry, Mr. Zuo Yuxing, founder and CEO of Tongee Medical, shared the practical application of the company in product innovation and technological innovation with the title of "History and Status Quo of Gastric Bypass Stent". Mr. Zuo Yuxing said that the core of the whole nutritional metabolism system of the human body lies in the intestine. The gastric bypass stent system independently developed by Tongee, physically isolates the contact between chyme and intestinal wall and reduces the absorption of sugar and fat; The deeper mechanism is that the gastric bypass stent system isolates the stimulation of food on the small intestine and the contact of nutrients, which promotes the remodeling of intestinal morphology and intestinal mucosal structure and the faster turnover of gastrointestinal cells; At the same time, as the food is not fully digested, it is diverted to the distal jejunum, which directly stimulates the secretion of GLP1 receptor in the empty ileum, promoting blood sugar reduction and weight loss; In addition, the implantation of the product will fundamentally improve the human intestinal flora, and the proportion of intestinal probiotics will increase significantly.

"At present, the function of the gastric bypass stent system has been actively explored in many indications such as weight loss, type 2 diabetes and nonalcoholic fatty liver disease, and its excellent clinical performance has also been recognized by the majority of surgeons; At the same time, the company also launched innovative products including "the Gen-3 gastric balloon, the new generation of water-absorbing gel", all of which are based on the intestine and stomach for interventional treatment of metabolic diseases; In the future, we hope to cooperate with more experts at home and abroad to continue to find the root cause of the relationship between gastrointestinal tract, especially intestine, and metabolism.” Mr. Zuo Yuxing said.

In order to help the surgeons master the application mode of the gastric bypass stent system, Professor Zhou Yanhua, deputy chief physician of the Department of Gastroenterology, Beijing Friendship Hospital affiliated to Capital Medical University, combining her own experience and actual cases, shared a theme report entitled "Clinical Implantation Methods and Efficacy of the Gastric Bypass Stent System", and gave a wonderful elaboration on the good operating practices, clinical practice experience and application case report of the gastric bypass stent system.

Professor Zhou Yanhua said in the sharing: With more than ten years of repeated exploration in the “gastric bypass stent system”, a lot of proved medical evidences have been obtained for validating the safety and effectiveness of its pre-clinical research: more than 380 repeated implantation and explanation tests in miniature pigs have been carried out, and no obvious adverse reactions have occurred; In 2021, Beijing Friendship Hospital affiliated to Capital Medical University conducted clinical trials on the innovative technology of “gastric bypass stent system” for metabolic diseases eligible for endoscopic interventional treatment. In real human clinical trials, it also showed good curative effect - 3 months after implanting the product, all patients showed healthy weight loss, and the weight changes from baseline were -8.0±3.6 kg, equivalent to 8.9±4.0% of the total weight. At the same time, it was observed that the glycosylated hemoglobin, hepatic steatosis, liver enzyme level, insulin resistance and metabolic parameters of the subjects were significantly decreased, and no obvious adverse reactions occurred^[1].

Finally, Professor Zhou showed the exact diagnosis and treatment effect of the gastric bypass stent system with two cases, and she looked forward to working with more medical peers to verify the clinical effect of the new technology in more metabolic diseases. “

At the meeting, Professor Zhao Xiangwen, vice president and director of the Weight Loss Center of Zhongshan Xiaolan People's Hospital, shared the theme report of "Doctor IP Value Chain Incubation Scheme in the Digital Age". At present, Tongee Medical is constantly exploring a new cooperation mode of medical treatment combination with an open-minded attitude, and its all-end digital health management platform [Enjoyluck Health] provides more possibilities for the efficient link between doctors and patients in the whole-course management mode.

This exchange meeting of the innovative therapy of gastric bypass stent from Tongee Medical demonstrated to the participating experts intuitively and clearly the exact curative effect of this innovative therapy, and also brought new enlightenment for clinicians to better formulate weight loss strategies.

References:

[1]Ren M, Zhou X, Yu M, Cao Y, Xu C, Yu C, Ji F. Prospective study of a new endoscopic duodenal-jejunal bypass sleeve in obese patients with nonalcoholic fatty liver disease (with video). Dig Endosc. 2022 Jul 23. doi: 10.1111/den.14409. Epub ahead of print. PMID: 35869797.